The key points:
Realistically, even if everything were to go perfectly, one shouldn’t expect that there would be any income from a PRV sale for at least three years.
Therefore, income from the sale of any PRV is certainly not going to fund Neuren’s planned Phase 2 trials of NNZ-2591 in three indications, which are supposed to commence before the end of this year.
Ann: Commentary on potential benefit to Neuren of RPD designation, page-21
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$12.85 |
Change
-0.110(0.85%) |
Mkt cap ! $1.598B | |||
| Open | High | Low | Value | Volume |
| $12.82 | $13.05 | $12.53 | $6.559M | 511.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 1657 | $12.83 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $12.85 | 6303 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2025 (20 minute delay) ? |
| NEU (ASX) Chart |